Imugene's Leslie Chong discusses with Proactive's Andrew Scott the appointment of Dr Steven Cha as Chief Medical Officer and a member of the company's executive management team. IMU has recently received a notice of grant from the Japanese Patent Office which protects its oncolytic virotherapy CF33, including VAXINIA (CF33-hNIS) and CHECKVacc (CF33-hNIS-antiPDL1). The company has also opened the doors to a large and lucrative market for immuno-oncology by securing a Notice of Grant from the European Patent Office for its HER-Vaxx immunotherapy.
Imugene welcomes new chief medical officer and talks significant new patents
